The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Are you running for office Tattyhead?
If I had been considering an investment in SNG but was holding off until the right moment, my FOMO would be through the roof today.
Even this is completely irrelevant (eh staff Christmas presents) it is the most bizarre and entertaining bit of sleuthing we’ve seen for a while!
So the phrase should be: ‘For every sell there is a market maker with a good understanding of the demand who is reasonably confident of finding a buyer, whether that means splitting the sale volume up into smaller transactions or bolting it onto a larger deal.’
Not quite as catchy.
Imagination is your planet gift, as the moon and Uranus team up — and inspire some wild and wonderful concepts. Don’t discount anything, as your ability to think outside the box is going to be in high demand. And a role with a link to the sky can be coming closer. An ex-neighbour is making a huge cash change - and may want to involve you.
Agree. The midday announcement about Ashfield might signal a move towards timing big news for the US market and decision makers.
There are other Respiratory Sales roles where they name the partner (Nestle). These roles don’t and keep us guessing.
A couple of these Respiratory Sales jobs were posted by Ashfield Engage 18 days ago, for a ‘leading pharmaceutical company’. May not be to distribute our product but interesting nonetheless (spread across US), and worth keeping an eye on.
Check out this job at Ashfield, part of UDG Healthcare: Specialty Respiratory Sales Representative
https://www.linkedin.com/jobs/view/2851279268
Does anyone have any examples of how long Parexel have taken to publish results on similar trials?
Keep an eye on this page over the next week or two just in case HMG are quicker to update it than an RNS from GDR. Last updated 24th December.
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/coronavirus-covid-19-serology-and-viral-detection-testing-uk-procurement-overview#products-in-the-pipeline-tvg
Yep - first time in a while that I’ve been offered a price for my entire holding in one go. Closer to the ask than the bid as well.
Does anyone know if BC have any other ‘exciting new COVID-19 ID Kit Point of Care assay’ coming online?
Positive spin? Err… how about a few weeks ago we were 17p?
NT…
NT….
Creep up half a point, small trade… then
NT…
NT…
Just logged on to find we are more than 7% up on previous close, after a dip this morning. I presume I don’t need to read the ~200 posts from today, documenting a load of bed-wetting during the tree shake?
Novacyt’s announcement was a 1230 RNS:
https://www.lse.co.uk/rns/NCYT/launch-of-ce-ivd-marked-novel-coronavirus-test-3kuv9ob3b0tupx3.html
Interesting. Could you direct us to the part of the P3 protocol that explains the futility assessment after 40% completion?
Thanks
But we know that they wouldn’t be progressing this to a trial on 600 people unless it showed benefit in P2. That would be unethical, to use their language. A reminder from the trial protocol:
Graduation of an investigational agent from phase II to phase III evaluation will be based on there being a desired level of evidence of an effect of an investigational agent versus placebo on one or more virologic and clinical outcome measures, as well as safety, as described below. The level of evidence required for the virology and clinical measures for agents evaluated in phase II of this protocol will be expressed in terms of Bayesian probability statements of the following form:
Probability (agent is better than placebo by at least X) is greater than 0.6 where X is defined below for each outcome measure. The choice of 0.6 for this probability indicates that there is a 3 to 2 odds of the agent being better than placebo for that parameter.
OK thanks Ndn